Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
2012 ◽
Vol 13
(3)
◽
pp. 239-246
◽
Keyword(s):
Phase 3
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8005-8005
◽
Keyword(s):
2016 ◽
Vol 17
(5)
◽
pp. 577-589
◽
Keyword(s):
Keyword(s):